Prosecution Insights
Last updated: November 17, 2026
Application No. 19/095,716

SYSTEMS AND METHODS FOR THERAPY ANNOTATION

Non-Final OA §112§DOUBLEPATENT
Filed
Mar 31, 2025
Priority
Jan 23, 2019 — provisional 62/796,012 +2 more
Examiner
HUPCZEY, JR, RONALD JAMES
Art Unit
3794
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Affera Inc.
OA Round
1 (Non-Final)
65%
Grant Probability
Moderate
1-2
OA Rounds
87%
With Interview

Examiner Intelligence

Grants 65% of resolved cases
65%
Career Allowance Rate
533 granted / 823 resolved
-5.2% vs TC avg
Strong +22% interview lift
Without
With
+22.5%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
36 currently pending
Career history
859
Total Applications
across all art units

Office Action

§112 §DOUBLEPATENT
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1-18 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Rgearding claim 1, the claim recites the limitation of “generating visual indicia at least in part on the determined first location and the determined second location”. The claim has also set forth the requirements of “determining a first location of at least one sensor of the two or more sensors” and “determining a second location of at least one sensor of the two or more sensors” therein. The Examiner is of the position that the highlighted portion of the claim renders the scope of the claim as indefinite as presently recited given that it is unclear how each of the “the first location” and the “the second location” recitations recite to the full scope of the determined first/second location when the full scope of the “at least one sensor of the two or more sensors” is taken into consideration. Said differently, if a location, whether first or second, is determined for more than one sensor of the two or more sensors, it is unclear to the Examiner if the latter recited “the determined first location” and “the determined second location” refers to such locations of each sensor, for only one sensor of the two or more sensors, or some other variation. The Examiner respectfully suggests language such as “generating visual indicia at least in part on the determined first location and the determined second location of the at least one sensor of the two or more sensors” to address the issues noted above. Claims 2-11 are rejected due to their dependency on claim 1. Appropriate correction is required. Regarding claim 11, the claim recites substantially similar limitations as have been noted with respect to claim 1 above with respect to the “a first location”, “a second location” and “the determined first location and the determined second location”. Thus, claim 11 is indefinite for at least the same reasoning as set forth with respect to claim 1 above. Claims 12-18 are rejected due to their dependency on claim 11. Appropriate correction is required. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 1-20 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 12-21 of U.S. Patent No. 12,268,456 B2. Although the claims at issue are not identical, they are not patentably distinct from each other because: Regarding instant claims 1, 11 and 19, the Examiner notes that patented claim 12 is particularly relevant to the subject matter set forth in each instant claim. Patented claim 12 is narrower in some aspects than each of instant claims 1, 11 and 19 and broader in other aspects. It is well established, with respect to the narrower aspects, that the generic invention of the instant claims are “anticipated” by the “species” of patented claims. See In re Goodman, 29 USPQ2d 2010 (Fed. Cir. 1993). With respect to the broader aspects, the Examiner notes that the difference between each of instant claims 1 and 11, and patented claim 12 exists in instant claim 1 defining a first therapy delivery signal and a second therapy delivery signal, and in instant claim 11 a first portion of a therapy delivery signal and a second portion of a therapy delivery signal, whereas patented claim 12 only sets forth a signal therapy delivery signal. The Examiner is of the position, however, that the provision of duplicating the therapy delivery signal as in the patented claim at different locations at a treatment site would have been an obvious consideration to one of ordinary skill in the art. Specifically, repeated locating of the distal end of the device when moving within the body is an obvious consideration to one of ordinary skill in the art when navigating within the body with the repeated measurement allowing for the assessment of movement of the distal tip as it is navigated as needed for treatment. The Examiner further notes that similar rationale is equally applicable to the broader aspects of instant clam 19 in view of patented claim 12. With respect to dependent claims 2-10, 12-18 and 20, see at least one of patented claims 13-21. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to RONALD HUPCZEY, JR whose telephone number is (571)270-5534. The examiner can normally be reached Monday - Friday; 8 am - 4 pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Joseph Stoklosa can be reached at (571) 272-1213. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /Ronald Hupczey, Jr./Primary Examiner, Art Unit 3794
Read full office action

Prosecution Timeline

Mar 31, 2025
Application Filed
Oct 21, 2026
Non-Final Rejection mailed — §112, §DOUBLEPATENT (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12788479
Tissue ablation guided by electrical impedance spectroscopy
2y 8m to grant Granted Nov 10, 2026
Patent 12765936
CONTROLLED NEUROMODULATION SYSTEMS AND METHODS OF USE
2y 5m to grant Granted Oct 20, 2026
Patent 12758153
OPTICAL FORCE SENSOR WITH A CATHETER/SHEATH
2y 6m to grant Granted Oct 13, 2026
Patent 12740819
DEPLOYABLE ASSEMBLY SLEEVE FOR ABLATION PROBE WITH DEPLOYABLE SENSORS
4y 10m to grant Granted Sep 22, 2026
Patent 12740836
ROBOTIC SURGICAL SYSTEM WITH INSTRUMENT BAILOUT AND LOCKOUT FEATURES
3y 8m to grant Granted Sep 22, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
65%
Grant Probability
87%
With Interview (+22.5%)
Low
PTA Risk
Based on 823 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month